Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Total Non-Current Liabilities (2020 - 2025)

Sonoma Pharmaceuticals has reported Total Non-Current Liabilities over the past 9 years, most recently at $4.7 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 25.62% year-over-year to $4.7 million; the TTM value through Dec 2025 reached $4.7 million, up 25.62%, while the annual FY2025 figure was $4.1 million, 6.34% up from the prior year.
  • Total Non-Current Liabilities for Q4 2025 was $4.7 million at Sonoma Pharmaceuticals, roughly flat from $4.7 million in the prior quarter.
  • Over five years, Total Non-Current Liabilities peaked at $6.3 million in Q1 2022 and troughed at $3.3 million in Q4 2023.
  • A 5-year average of $4.5 million and a median of $4.3 million in 2022 define the central range for Total Non-Current Liabilities.
  • Biggest five-year swings in Total Non-Current Liabilities: plummeted 36.31% in 2023 and later soared 38.62% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $4.4 million in 2021, then dropped by 3.5% to $4.3 million in 2022, then fell by 21.93% to $3.3 million in 2023, then grew by 12.8% to $3.8 million in 2024, then increased by 25.62% to $4.7 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for SNOA at $4.7 million in Q4 2025, $4.7 million in Q3 2025, and $5.3 million in Q2 2025.